Horizon sues Actavis over inflammation cream

Ireland-based Horizon Pharma has filed a complaint against Actavis for patent infringement.

The case was filed on Thursday, May 11, at the US District Court for the District of New Jersey.

Horizon sued Actavis after it filed an Abbreviated New Drug Application (ANDA) with the Food and Drug Administration (FDA).

According to the complaint, Actavis sought permission to market a generic version of Horizon’s Pennsaid (diclofenac sodium) prior to the expiration of US patent number 9,539,335, which belongs to Horizon.

Pennsaid is a treatment cream for pain and inflammation.

Horizon has asked the district court for a ruling in its favour, as well as an order preventing FDA approval prior to the expiration of the patent involved.

Did you enjoy reading this story?  Sign up to our free newsletter and get stories like this sent straight to your inbox.